Agreement: I Agree Body: Dear Editor It is apparent that RSV vaccination with RSVpreF (Abrysvo), as currently recommended in the UK, is reasonably safe, and effective at reducing hospital admissions due to RSV respiratory tract disease in adults aged 60 and older. The same study that showed this benefit also showed that there was an imbalance in deaths from all causes in the vaccinated group. Supplementary table S3 of the study findings (1) shows, that for the additional secondary objective of the trial, there were 152 deaths in the 65,648 vaccinated subjects (0.23%) compared with 129 deaths in 65,644 unvaccinated controls (0.20%). 1 Lassen MCH, Johansen MD, Christiansen MH et al. RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. New England Journal of Medicine 2026;394:138-151 DOI: 10.1056/NEJMoa2509810 No competing Interests: Yes The following competing Interests: Electronic Publication Date: Sunday, April 5, 2026 - 07:59 AI use: No, I have not used AI Highwire Comment Subject: RSV vaccination programme expanded to 3 million more older people Workflow State: Released Full Title: Re: RSV vaccination programme expanded to 3 million more older people Highwire Comment Response to: RSV vaccination programme expanded to 3 million more older people Check this box if you would like your letter to appear anonymously:: Last Name: Selley First name and middle initial: Peter J Email: peterjselley@gmail.com Address: Crediton, Devon Occupation: Retired GP BMJ: Additional Article Info: Rapid response